New drug combo tested for tough cancers
NCT ID NCT00600496
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researchers also studied how the drugs move through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6244 (also called ARRY-142886) combined with standard chemotherapies
What this could lead to
If successful, this could point toward a new combination treatment option for advanced solid tumors.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The combination may cause side effects or not work against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States